Acumen Pharmaceuticals (ABOS) Net Cash Flow (2020 - 2026)

Acumen Pharmaceuticals' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 59.89% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at $21.6 million (up 228.99% YoY), while the FY2025 annual figure was $18.4 million, up 158.74% from the prior year.
• Net Cash Flow came in at -$2.2 million for Q1 2026 at Acumen Pharmaceuticals, down from $7.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $46.5 million in Q3 2022 to a low of -$52.1 million in Q1 2023.
• A 5-year average of -$4.1 million and a median of -$751000.0 in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 465.32% in 2022 and surged 2899.73% in 2024, its largest moves.
• Acumen Pharmaceuticals' Net Cash Flow stood at -$27.4 million in 2022, then declined by 2.0% to -$28.0 million in 2023, then surged by 108.71% to $2.4 million in 2024, then jumped by 193.4% to $7.2 million in 2025, then tumbled by 130.65% to -$2.2 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$2.2 million, $7.2 million, and $10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison